QUANTITATIVE SPECTROSCOPIC AND ANATOMIC PROSTATE IMAGING AT 7 TESLA

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 前列腺癌是男性最常见的癌症，每六个人中就有一个会在一生中被诊断出患有前列腺癌。尽管其流行，但很少有诊断工具，主要是活检和血清PSA，存在着监测疾病进展和确定治疗成功的工具。活检虽然能够对前列腺进行局部监测，但具有侵袭性，而且低估了疾病的级别和程度，而PSA缺乏特异性。改进的监测疾病状态的方法将极大地有利于前列腺癌的管理，因为它将不必要的治疗和相关的发病率降至最低，并提供治疗后局部复发的早期迹象。这项研究的主要目标是1)开发一个7特斯拉(7T)前列腺平台，包括开发和评估几个相互依赖的组件：射频线圈、新颖的解剖和光谱成像方法以及光谱量化技术，以及2)验证新提出的定量生物标记物作为检测疾病、确定疾病范围和评估侵袭性的敏感工具。通过利用优化的超高场(7T)前列腺成像平台提高的空间和光谱分辨率，我们的预期成果是能够跟踪前列腺癌生物标记物的微小变化，这些生物标记物对于1)在主动监测研究期间确定癌症从惰性疾病到具有生物学意义的疾病的转变非常重要，2)监测治疗以定量评估新疗法并指导“患者定制”策略。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. ) Prostate cancer is the most common cancer in men where one in six will be diagnosed with the disease in their lifetime. Despite its prevalence, few diagnostic tools, mainly biopsy and serum PSA, exist for monitoring disease progression and determining treatment success. Biopsies, while able to locally monitor the prostate, are both invasive and underestimate grade and extent of disease while PSA lacks specificity. Improved methods to monitor the disease state would greatly benefit prostate cancer management by minimizing the need for unnecessary treatment and associated morbidity and by providing early indication of local recurrence after treatment. The main objectives of this research is to 1) develop a 7 Tesla (7T) prostate platform including the development and evaluation of several interdependent components: RF coils, novel anatomic and spectroscopic imaging methods and spectral quantification techniques and 2) validate the newly proposed quantitative biomarkers as sensitive tools to detect disease, determine extent and assess aggressiveness. By taking advantage of the increased spatial and spectral resolution of an optimized ultra-high field (7T) prostate imaging platform, our expected outcome is the ability to track small changes in prostate cancer biomarkers important for 1) determining the transition of cancer from indolent to biologically significant disease during active surveillance studies and 2) monitoring treatment to quantitatively evaluate new therapies and guide "patient-tailored" strategies.